Viewing StudyNCT03070093



Ignite Creation Date: 2024-05-06 @ 9:48 AM
Last Modification Date: 2024-10-26 @ 12:19 PM
Study NCT ID: NCT03070093
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2021-04-20
First Post: 2017-02-28

Brief Title: Expanded Access Study of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD
Sponsor:
Organization: Astellas Pharma Inc

Study Design

Study Type: EXPANDED_ACCESS
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: True
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: None
Enrollment Type: None
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: